Cases from the Clinic(ians): Case-Based Panel Discussion
|
|
- Bernard Logan
- 5 years ago
- Views:
Transcription
1 Cases from the Clinic(ians): Case-Based Panel Discussion Michael S. Saag, MD Professor of Medicine The University of Alabama at Birmingham EDITED: Learning Objectives After attending this presentation, learners will be able to: Know when to initiate therapy for acute HIV infection Define the timing of discontinuation of primary prophylaxis Describe the biology of HIV in the setting of ARV therapy Slide 3 of 50 Slide 4 of 50 Should I treat patients with acute seroconversion syndrome, and if so, when and with what ARV therapy? Page 1 of 17
2 Case 1 Slide 5 of yo man presents with mononucleosis-like illness Febrile, faint rash on chest, pharyngeal edema, diffuse lymphadenopathy Combo Ab/Ag Test: HIV Ab Negative P24 Ag Positive Slide 6 of 50 At this point you would order confirmatory HIV RNA, genotypic resistance test, and: 1. Hold ARV Rx until lab tests return 2. Start ARV Rx with 2 nucs and an NNRTI 3. Start ARV Rx with 2 nucs and a boosted PI 4. Start ARV Rx with 2 nucs and an STII (integrase inhibitor) 5. Not give ARV Rx until otherwise indicated Slide 7 of 50 Natural History and Laboratory Staging of HIV Infection Eclipse Phase I II III IV V VI v RNA+ (Fiebig, AIDS 2003) Western blot +/- Western blot + (p31-) Western + (p31+) Keele et al., PNAS 2008 Page 2 of 17
3 CROI 2014: Acute Infection Slide 8 of 50 Sigmoid Biopsies: Significantly lower frequency of Th17 cells was observed in FIII compared to FI/ II (Median 7.1% vs. 13.2%, p=0.03) (Schuetz Abstract 77) Initiation of ART at very early stages of infection (Fiebig I) impeded seroconversion to anti-hiv antibody. Initiation of ART at Fiebig II-V delayed evolution of serological markers (Manak Abst 395) Extremely Early Initiation of ART (~Day10) HIV RNA/DNA tests have been negative, including those performed in colorectal biopsy Samples enriched for total CD4+ T cells and CD4+ T cell subsets (Tn, Tcm, Ttm, Tem) from leukapheresis were also negative for HIV RNA and DNA (Cheret Abst 398) Slide 9 of Slide 9 of 52 Slide 10 of 52 Slide 10 of 50 Page 3 of 17
4 Slide 11 of 52 Slide 11 of 50 Slide 12 of 52 Slide 12 of 50 Slide 13 of 52 Slide 13 of 50 Page 4 of 17
5 Slide 14 of Viral Load T 1/2 = 1.1 days Slide 14 of Weeks Slide 15 of 50 What do I do for patients who have virologic success but a poor CD4 count response? Case 2 Slide 16 of yo female started on TDF / FTC / ATZ / rit 3 years ago Initial: Now: HIV RNA 78,000 c/ml CD4 count 80 cells/ul HIV RNA < 50 c/ml (persistently) CD4 167 cells/ul She is tolerating the regimen well Page 5 of 17
6 At this point you would: Slide 17 of Continue her current ARV Rx 2. Change her ARV Rx to 2 nucs and an NNRTI 3. Change her ARV Rx to 2 nucs and a different boosted PI 4. Change her ARV Rx to 2 nucs and an STII (integrase inhibitor) 5. Change her ARV Rx to an STII and a different boosted PI 6. Something else What is Immunologic Failure? 6 weeks 3 months 2 years 3 years Slide 18 of 50 Slide 19 of 50 Can I stop PCP prophylaxis in a patient with a good virologic response but immunologic failure? Page 6 of 17
7 Case 3 Slide 20 of yo female started on TDF / FTC /ATZ / rit 3 years ago Initial: Now: HIV RNA 78,000 c/ml CD4 count 80 cells/ul HIV RNA < 50 c/ml (persistently) CD4 167 cells/ul (CD4 % = 12%) She remains on TMP/ SMX primary prophylaxis, one DS tablet daily and tolerating it well At this point you would: Slide 21 of Continue her current TMP/SMX Rx 2. Change her Rx to 1 DS tablet every other day 3. Stop all PCP prophylaxis 4. Call Dr. Friedland Slide 22 of 50 Page 7 of 17
8 Conclusions: The virus is Evil: Replication: Bad Suppression: Good CD4 count cutoffs for PCP prophylaxis established prior to effective ARV Rx Slide 23 of 50 In setting where VL < 50, PCP prophylaxis can be safely stopped when CD4 > 100 cells Slide 24 of 50 In a patient with elevated lipids, do I change the antiretroviral therapy or add lipid therapy? Case 4 56 yo male started on ARV Rx many years ago (unknown resistance history) Has been through multiple regimens; now on TDF / FTC / Lop / rit Non-Smoker / Neg PMH / Neg Fam Hx for CAD Now: Slide 25 of 50 HIV RNA < 50 c/ml (persistently) CD4 560 cells/ul Cholesterol 220 mg/dl (HDL 38 / LDL 122) Triglycerides 540 mg/dl Page 8 of 17
9 At this point you would: 1. Continue her current ARV Rx 2. Change her Lop/Rit to DRV/Rit 3. Change her Lop/Rit to an SSTI 4. Start a statin 5. 1 and and and 4 8. None of the above Slide 26 of 50 Case 5 56 yo male started on ARV Rx many years ago (unknown resistance history) Has been through multiple regimens; now on TDF / FTC / DRV / rit Non-Smoker / H/o DM / Neg Fam Hx for CAD Now: Slide 27 of 50 HIV RNA < 50 c/ml (persistently) CD4 560 cells/ul Cholesterol 220 mg/dl (HDL 38 / LDL 122) Slide 28 of 50 In addition to starting a statin, you would: 1. Continue her current ARV Rx 2. Change her DRV/Rit to NNRTI 3. Change her DRV/Rit to an SSTI 4. Some other option Page 9 of 17
10 Slide 29 of 50 What is the current status of use of abacavir in a patient with CV risk factors? Case 6 56 yo male started on ARV Rx many years ago (resistance history no known PI mutations) Has been through several regimens; now on ABC / 3TC / Dolutegravir Smoker / Diabetic / + Fam Hx for CAD Now: Slide 30 of 50 HIV RNA < 50 c/ml (persistently) CD4 560 cells/ul Cholesterol 220 mg/dl (HDL 38 / LDL 122) Slide 31 of 50 In addition to starting a statin, you would: 1. Continue her current ARV Rx 2. Change her ABC/3TC to TDF/FTC 3. Change her ABC/3TC to DRV/rit 4. Some other option Page 10 of 17
11 Clinical experience with DRV/r + DTG Slide 32 of 50 There is no effect of DTG on DRV/r PK DRV/r 600/100 BID lowers DTG Cmin by 38%. This is not considered clinically significant, given the 50mg OD dose of DTG used DRV/r + integrase proof of principle: NEAT (DRV/r + RAL vs DRV/r + TDF/FTC) (CROI 2014) DRV/r + DTG + 2 Nucs was the most common combination used in the SAILING Trial (Lancet 2013, 382, ) Slide 33 of 50 What is the best initial ARV therapy for a patient with baseline CKD? Case 7 Slide 34 of yo male newly diagnosed HIV resistance assay reveals wild type virus Smoker / H/o DM / Neg Fam Hx for CAD HIV RNA 128,000 c/ml CD4 count 280 cells/ul S-creatinine 2.1 mg/dl (ecrcl = 48 cc/min) Page 11 of 17
12 What ARV regimen would you start? 1. TDF every other day, FTC, EFV 2. TDF every other day, FTC, DRV/rit 3. ABC / 3TC / EFV 4. ABC / 3TC / DRV/rit 5. ABC / 3TC / DTG 6. TDF / FTC / ELV / cobi 7. ABC / FTC / DRV/rit 8. DRV/rit / RAL 9. DRV/rit / DTG 10. Some other option Slide 35 of 50 Slide 36 of 50 What is the best way to manage chronic HBV infection in a patient with CKD? Case 8 Slide 37 of yo male newly diagnosed HIV resistance assay reveals wild type virus Smoker / H/o DM / Neg Fam Hx for CAD HIV RNA 128,000 c/ml CD4 count 280 cells/ul S-creatinine 2.1 mg/dl (ecrcl = 48 cc/min) HBsAb+ / HBsAg+ / HBeAg- Page 12 of 17
13 Slide 38 of 50 With regard to treating the HBV, what is the best approach? 1. TDF every other day in the regimen 2. FTC in the regimen (no other nuc) 3. 3TC in the regimen (no other nuc) 4. Entecavir in addition to the ARV Rx 5. Adefovir in addition to the ARV Rx 6. PEG-IFN weekly in addition to the ARV Rx for 48 weeks 7. No need to Rx for HBV in this setting 8. Some other option Slide 39 of 50 How do I best use resistance test results, especially in a patient with a baseline K65R? Case 9 56 yo male started on ARV Rx many years ago (resistance history no known PI mutations) Has been through several regimens; now on TDF / FTV / ETV Smoker / Diabetic / + Fam Hx for CAD VL Max: 240,000 c/ml / CD4 nadir 5 cells/ul Slide 40 of 50 Now: HIV RNA 1200 c/ml (confirmed) CD4 160 cells/ul Page 13 of 17
14 Slide 41 of 50 Which ARV regimen would you choose: 1. ABC / 3TC / EFV 2. ABC / 3TC / DTG 3. ABC / 3TC / DRV/ rit 4. TDF / FTC / ELV / cobi 5. TDF / FTC / EFV 6. TDF / FTC / DRV / rit 7. RAL / DRV/ rit +/- FTC 8. DTG / DRV/ rit +/- FTC 9. Another choice What ARV regimen would you use now? 1. TDF, FTC, ATZ/rit 2. TDF, FTC, DRV/rit 3. ABC / 3TC / DRV/rit 4. ABC / 3TC / DTG 5. TDF / FTC / ELV / cobi 6. TDF / ZDV / DRV/rit 7. ZDV / DRV/rit / DTG 8. DRV/rit / DTG / FTC 9. Some other option Slide 42 of 50 Slide 43 of 50 Can I simplify the ARV regimen of an ARV experienced patient who is now under virologic control? Page 14 of 17
15 Case yo male started on ARV Rx many years ago (3 class resistance by history; 184V, K103N, Y181C, D30N) Slide 44 of 50 Has been through several regimens; has been on ZDV / TDF / FTC / DRV/rit / RTG VL Max: 240,000 c/ml / CD4 nadir 5 cells/ul Now: HIV RNA <50 c/ml (for 3 years) CD4 360 cells/ul Slide 45 of 50 With regard to simplifying the regimen, you would: 1. Continue her current ARV Rx (GHWB) 2. Stop the ZDV and cont TDF/ FTC / DRV/rit / RTG 3. Stop the ZDV and cont TDF/ FTC / DRV/rit 4. Stop the ZDV and cont TDF/ FTC / RTG 5. Stop the TDF and cont ZDV/ FTC / DRV/rit / RTG 6. Some other option Slide 46 of 50 What will be the right approach for selection of initial ARV Rx when more drugs become generic? Page 15 of 17
16 Case 11 Slide 47 of yo male newly diagnosed HIV resistance assay reveals wild type virus Non-Smoker / Neg PMH/ Neg Fam Hx for CAD HIV RNA 128,000 c/ml CD4 count 280 cells/ul S-creatinine 0.9 mg/dl HBsAb+ / HBcAb- / HBsAg- What ARV regimen would you start? Slide 48 of Generic ZDV, 3TC, EFV 2. Brand TDF + Generic 3TC, EFV 3. Generic ABC + 3TC + EFV 4. Brand TDF / FTC / EFV (FDC) 5. Brand TDF / FTC / ELV / cobi (FDC) 6. Brand ABC / 3TC / DTG (FDC) 7. Some other option Patent expiration dates for HIV drugs Slide 49 of 50 The original 20 year patents for most key antiretrovirals have already expired, or will expire in the next 3-4 years. Walensky, 49 et al, Ann Int Med 158, 2013 Page 16 of 17
17 Slide 50 of 50 Patent expiration dates for HIV drugs 2012: ZDV, 3TC, d4t, ddi, SQV, NVP generic 2013: ritonavir, efavirenz, ZDV/3TC generic 2016: abacavir, LPV/r (soft-gel) 2017: atazanavir, tenofovir, darunavir 2019: etravirine, ABC/3TC 2024: TDF/FTC 2025: raltegravir 2026: TDF/FTC/EFV, TDF/FTC/RPV, dolutegravir Ref: Medecins Sans Frontieres 2013: Untangling the web of ARV price reductions Page 17 of 17
Panelists Melanie Thompson Jeffrey Lennox Wendy Armstrong Jonathan Li
Slide 1 of 51 Interactive ART Cases From the Clinic(ians): Case-Based Panel Discussion Michael S. Saag, MD Professor of Medicine Associate Dean for Global Health Jim Straley Chair in AIDS Research University
More informationAntiretroviral Therapy Interactive Cases From the Clinic(ians): Case-Based Panel Discussion
Slide 1 of 51 Antiretroviral Therapy Interactive Cases From the Clinic(ians): Case-Based Panel Discussion Michael S. Saag, MD Professor of Medicine Associate Dean for Global Health University of Alabama
More informationHIV 101. Applications of Antiretroviral Therapy
HIV 101. Applications of Antiretroviral Therapy Michael S. Saag, MD Professor of Medicine Associate Dean for Global Health Jim Straley Chair in AIDS Research University of Alabama at Birmingham Birmingham,
More informationTreating HIV in 2018 Interactive Cases From the Clinic(ians)
Slide 1 of 51 Treating HIV in 2018 Interactive Cases From the Clinic(ians) Michael S. Saag, MD Professor of Medicine Associate Dean for Global Health Jim Straley Chair in AIDS Research University of Alabama
More informationSwitching ARV Regimens: Managing Toxicity and Improving Tolerability; Switches & Class-Sparing Approaches
Switching ARV Regimens: Managing Toxicity and Improving Tolerability; Switches & Class-Sparing Approaches Harry W. Lampiris, MD Chief, Infectious Disease Section, San Francisco VA Medical Center Professor
More informationComprehensive Guideline Summary
Comprehensive Guideline Summary Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents AETC NRC Slide Set Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and
More informationHIV Treatment: New and Veteran Drugs Classes
HIV Treatment: New and Veteran Drugs Classes Jonathan M Schapiro, MD National Hemophilia Center Stanford University School of Medicine Rome, March 2013 Overview Many excellent antiretroviral agents are
More informationThe use of antiretroviral agents during pregnancy in Canada and compliance with North-American guidelines
The use of antiretroviral agents during pregnancy in Canada and compliance with North-American guidelines I. Boucoiran, T. Lee, K. Tulloch, L. Sauve, L. Samson, J. Brophy, M. Boucher and D. Money For and
More informationThe next generation of ART regimens
The next generation of ART regimens By Gary Maartens Presented by Dirk Hagemeister Division of Clinical Pharmacology UNIVERSITY OF CAPE TOWN IYUNIVESITHI YASEKAPA UNIVERSITEIT VAN KAAPSTAD Current state
More informationPediatric HIV Update NORTHWEST AIDS EDUCATION AND TRAINING CENTER
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Pediatric HIV Update Christian B. Ramers, MD, MPH Assistant Medical Director, Family Health Centers of San Diego HIV/HCV Distance Education Specialist - NWAETC,
More informationAntiretroviral Treatment Strategies: Clinical Case Presentation
Antiretroviral Treatment Strategies: Clinical Case Presentation Department of Internal Medicine, Far Eastern Memorial Hospital, New Taipei City, Taiwan Chia-Jui, Yang M.D Disclosure No conflicts of interests.
More information2 nd Line Treatment and Resistance. Dr Rohit Talwani & Dr Dave Riedel 12 th June 2012
2 nd Line Treatment and Resistance Dr Rohit Talwani & Dr Dave Riedel 12 th June 2012 Overview Basics of Resistance Treatment failure Strategies to manage treatment failure Mutation Definition: A change
More informationContinuing Education for Pharmacy Technicians
Continuing Education for Pharmacy Technicians HIV/AIDS TREATMENT Michael Denaburg, Pharm.D. Birmingham, AL Objectives: 1. Identify drugs and drug classes currently used in the management of HIV infected
More informationWhat's new in the WHO ART guidelines How did markets react?
WHO 2013 ARV Guidelines What's new in the WHO ART guidelines How did markets react? Dr. J. Perriëns Coordinator, HIV Technology and Commodities HIV department, WHO, Geneva When to start in adults Starting
More informationAntiretroviral Therapy: What to Start
FLOWED: 05-14-2015 Chicago, IL: May 18, 2015 Antiretroviral Therapy: What to Start Eric S. Daar, MD Professor of Medicine David Geffen School of Medicine University of California Los Angeles Los Angeles,
More informationPediatric HIV Infection and the Medical Management of Pregnant Women infected with HIV. Ernesto Parra, M.D., M.P.H.
Pediatric HIV Infection and the Medical Management of Pregnant Women infected with HIV Ernesto Parra, M.D., M.P.H. Adjunct Associate Professor UTHSCSA Department of Pediatrics and Family and Community
More informationReal Life Experience of Dolutegravir and Lamivudine Dual Therapy As a Switching Regimen in HIVTR Cohort
Real Life Experience of Dolutegravir and Lamivudine Dual Therapy As a Switching Regimen in HIVTR Cohort Yagci-Caglayik D 1, Gokengin D 2, Inan A 3, Ozkan-Ozdemir H 4, Inan D 5, Akbulut A 6, Korten V 1,
More informationPharmacological considerations on the use of ARVs in pregnancy
Pharmacological considerations on the use of ARVs in pregnancy 11 th Residential Course on Clinical Pharmacology of Antiretrovirals Torino, 20-22 January 2016 Prof. David Burger, PharmD, PhD david.burger@radboudumc.nl
More informationSTRIBILD (aka. The Quad Pill)
NORTHWEST AIDS EDUCATION AND TRAINING CENTER STRIBILD (aka. The Quad Pill) Brian R. Wood, MD Medical Director, NW AETC ECHO Assistant Professor of Medicine, University of Washington Presentation prepared
More informationSusan L. Koletar, MD
HIV/AIDS Susan L. Koletar, MD Division Director, Infectious Diseases Professor of Internal Medicine Department of Internal Medicine The Ohio State University Wexner Medical Center HIV through the Decades
More informationAre the current doses of ARV correct. Richard Elion MD Associate Adjunct Clinical Professor of Medicine Johns Hopkins School of Medicine
Are the current doses of ARV correct Richard Elion MD Associate Adjunct Clinical Professor of Medicine Johns Hopkins School of Medicine Can we lower doses of HIV meds safely? Consensus Panel in Alexandria
More information2016 Perinatal Treatment Guidelines Update
Mountain West AIDS Education and Training Center 2016 Perinatal Treatment Guidelines Update Shireesha Dhanireddy, MD Associate Professor of Medicine, University of Washington 2 November 2016 This presentation
More informationHIV Treatment: State of the Art 2013
HIV Treatment: State of the Art 2013 Daniel R. Kuritzkes, MD Chief, Division of Infectious Diseases Brigham and Women s Hospital Professor of Medicine Harvard Medical School Success of current ART Substantial
More informationCase # 1. Case #1 (cont d)
Antiretroviral Therapy Management: Expert Panel Discussion George Beatty Susa Coffey Steve O Brien December 3, 2011 Moderated by Annie Luetkemeyer Case # 1 38 y.o. man, CD4 =350, VL=340K, new to your clinic
More informationHIV - Therapy Principles
HIV - Therapy Principles Manuel Battegay and Christine Katlama Basel, Switzerland and Paris, France Disclosure MB has received honoraria for advisory board participation from Gilead, MSD, Pfizer, ViiV
More informationRajesh T. Gandhi, M.D.
HIV Treatment Guidelines: 2010 Rajesh T. Gandhi, M.D. Case 29 yo M with 8 weeks of cough and fever. Diagnosed with smear-positive pulmonary TB. HIV-1 antibody positive. CD4 count 361. HIV-1 RNA 23,000
More informationSusan L. Koletar, MD
HIV/AIDS Susan L. Koletar, MD Division Director, Infectious Diseases Professor of Internal Medicine Department of Internal Medicine The Ohio State University Wexner Medical Center HIV through the Decades
More informationSimplifying HIV Treatment Now and in the Future
Simplifying HIV Treatment Now and in the Future David M. Hachey, Pharm.D., AAHIVP Professor Idaho State University Department of Family Medicine Nothing Disclosure 1 Objectives List current first line
More information2/10/2015. Switching from old regimens. HIV treatment revision: As simple as old versus new? What is an old regimen? What is an old regimen?
Switching from old regimens David Nolan Department of Immunology, Royal Perth Hospital, Western Australia Institute for Immunology and Infectious Diseases, Murdoch University, Western Australia What is
More information12th European AIDS Conference / EACS ARV Therapies and Therapeutic Strategies A CME Newsletter
EACS 2009 11-14, November 2009 Cologne, Germany Course Director Jürgen K. Rockstroh, MD Co-Chairman, 12th European AIDS Conference Professor, University of Bonn Bonn, Germany Faculty Calvin Cohen, MD,
More informationThird Agent Advantages Disadvantages. Component Tenofovir/emtricitabine (TDF/FTC) 300/200 mg (coformulated with EFV as Atripla) 1 tab once daily
Table I. Recommended and Alternative Antiretroviral Regimens (DHHS Guidelines, May 1, 2014) Recommended Regimens Nucleoside Analog Reverse Transcriptase Inhibitor (NRTI) Third Agent Advantages Disadvantages
More informationPrima linea: dovremmo evitare i PI nella terapia di prima linea per i loro effetti non desiderati? Giuseppina Liuzzi
6 th INFECtivology TOday Paestum 15-16 -17 maggio 2014 Prima linea: dovremmo evitare i PI nella terapia di prima linea per i loro effetti non desiderati? Giuseppina Liuzzi Istituto Nazionale per le Malattie
More informationDidactic Series. CROI 2014 Update. March 27, 2014
Didactic Series CROI 2014 Update Christian Ramers, MD, MPH Family Health Centers of San Diego Ciaccio Memorial Clinic Jacqueline Peterson Tulsky, MD UCSF Positive Health Program at SFGH Medical Director,
More informationFriday afternoon Programme
Friday afternoon Programme Pharmacology and TDM Dr Marta Boffito Consultant Physician, C&W Resistance to new anti-retrovirals Dr Steve Taylor Consultant Physician, Birmingham HIVPA Annual Conference 2008
More informationSomnuek Sungkanuparph, M.D.
HIV Drug Resistance Somnuek Sungkanuparph, M.D. Associate Professor Division of Infectious Diseases Department of Medicine Faculty of Medicine Ramathibodi Hospital Mahidol University Adjunct Professor
More informationHIV Treatment Evolution. Kimberly Y. Smith MD MPH Vice President and Head, Global Research and Medical Strategy Viiv Healthcare
HIV Treatment Evolution Kimberly Y. Smith MD MPH Vice President and Head, Global Research and Medical Strategy Viiv Healthcare Overview of the Evolution of Antiretroviral Therapy Early Treatment 1987
More informationHIV Treatment Update. Awewura Kwara, MD, MPH&TM Associate Professor of Medicine and Infectious Diseases Brown University
HIV Treatment Update Awewura Kwara, MD, MPH&TM Associate Professor of Medicine and Infectious Diseases Brown University Outline Rationale for highly active antiretroviral therapy (HAART) When to start
More informationHIV Treatment Update. Anton Pozniak Consultant Physician, Director of HIV Services Chelsea and Westminster Hospital, London
HIV Treatment Update Anton Pozniak Consultant Physician, Director of HIV Services Chelsea and Westminster Hospital, London Guidelines Nuke sparing Nukes Efavirenz placement as the gold standard ARV Role
More informationWhat are the most promising opportunities for dose optimisation?
What are the most promising opportunities for dose optimisation? Andrew Hill Liverpool University, UK Global Financial Crisis How can we afford to treat 15-30 million people with HIV in the future? Lowering
More informationGuidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents
Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents Visit the AIDSinfo website to access the most up-to-date guideline. Register for e-mail notification of guideline
More informationUpdate on Antiretroviral Treatment for HIV Infection 2008
Update on Antiretroviral Treatment for HIV Infection 2008 Janet Gilmour MD FRCP(C) Clinical Associate Professor of Medicine University of Calgary November 2008 Disclosure and Acknowledgements Disclosure:
More informationTreatment of HCV in HIV/HCV Coinfection
Treatment of HCV in HIV/HCV Coinfection Michael S. Saag, MD Associate Dean, Global Health Professor of Medicine Director, Center for AIDS Research University of Alabama at Birmingham Birmingham, Alabama
More informationResistance Workshop. 3rd European HIV Drug
3rd European HIV Drug Resistance Workshop March 30-April 1 st, 2005 Christine Hughes, PharmD Clinical Associate Professor Faculty of Pharmacy & Pharmaceutical Sciences University of Alberta Tenofovir resistance
More informationOptimizing 2 nd and 3 rd Line Antiretroviral Therapy in Children and Adolescents
Optimizing 2 nd and 3 rd Line Antiretroviral Therapy in Children and Adolescents Victor Musiime, MBChB, MMED, PhD Senior Lecturer, Makerere University Investigator, Joint Clinical Research Centre (JCRC)
More informationART and Prevention: What do we know?
ART and Prevention: What do we know? Biomedical Issues Trip Gulick, MD, MPH Chief, Division of Infectious Diseases Professor of Medicine Weill Cornell Medical College New York City ART for Prevention:
More informationSimplifying Antiretroviral Therapy Regimens: It s not so simple
Simplifying Antiretroviral Therapy Regimens: It s not so simple Jonathan Colasanti, MD, MSPH Division of Infectious Diseases Emory University School of Medicine Disclosures No Financial Disclosures Parts
More informationTDF containing ART: Efficacy and Safety. Dr Lloyd B. Mulenga Adult Infectious Diseases Centre University Teaching Hospital Lusaka, Zambia
TDF containing ART: Efficacy and Safety Dr Lloyd B. Mulenga Adult Infectious Diseases Centre University Teaching Hospital Lusaka, Zambia 1 Indications Treatment of HIV-1 in combination with other antiretroviral
More informationMore Options, Some Opinions Initial Therapies for HIV Judith S. Currier, MD
More Options, Some Opinions Initial Therapies for HIV Judith S. Currier, MD More Options, Some Opinions: Initial Therapies for HIV Judith S. Currier, MD University of California Los Angeles Los Angeles,
More informationManagement of patients with antiretroviral treatment failure: guidelines comparison
The editorial staff Management of patients with antiretroviral treatment failure: guidelines comparison A change of therapy should be considered for patients if they experience sustained rebound in viral
More informationAntiretroviral Treatment 2014
Activity Code FM285 Antiretroviral Treatment 2014 Rajesh Gandhi, MD Masssachusetts General Hospital Disclosures: Educational grants to my institution from Janssen, Viiv, Abbott Learning Objectives Upon
More informationSecond-Line Therapy NORTHWEST AIDS EDUCATION AND TRAINING CENTER
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Second-Line Therapy David Spach, MD Clinical Director, Northwest AETC Professor of Medicine, Division of Infectious Diseases University of Washington Presentation
More informationDisclosures. Update on HIV Drug Therapy: A Case based Discussion. Case # 1: Dr. Grant has received grant support from BMS, Gilead, Janssen, and Viiv
Disclosures Update on HIV Drug Therapy: A Case based Discussion Dr. Grant has received grant support from BMS, Gilead, Janssen, and Viiv Philip Grant Assistant Professor Division of Infectious Diseases
More informationIntegrase Strand Transfer Inhibitors on the Horizon
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Integrase Strand Transfer Inhibitors on the Horizon David Spach, MD Clinical Director, Northwest AETC Professor of Medicine, University of Washington Presentation
More informationARVs on an Empty Stomach: Food Interaction Studies in a resource Limited Setting
ARVs on an Empty Stomach: Food Interaction Studies in a resource Limited Setting Dr. Andrew D Kambugu, FRCP (UK) Infectious Diseases Institute, Makerere University Outline of Discussion Key Definitions
More informationManagement of Treatment-Experienced Patients: New Agents and Rescue Strategies. Joel E. Gallant, MD, MPH Johns Hopkins University School of Medicine
Management of Treatment-Experienced Patients: New Agents and Rescue Strategies Joel E. Gallant, MD, MPH Johns Hopkins University School of Medicine When to Modify Therapy! Studies to date show better responses
More information2nd line failure, provincial evaluation process for 3rd line therapy, 3rd line treatment options James Nuttall
2nd line failure, provincial evaluation process for 3rd line therapy, 3rd line treatment options James Nuttall Paediatric Infectious Diseases Unit, Red Cross War Memorial Children s Hospital & University
More informationMDR HIV and Total Therapeutic Failure. Douglas G. Fish, MD Albany Medical College Albany, New York Cali, Colombia March 30, 2007
MDR HIV and Total Therapeutic Failure Douglas G. Fish, MD Albany Medical College Albany, New York Cali, Colombia March 30, 2007 Objectives Case study Definitions Fitness Pathogenesis of resistant virus
More informationDidactic Series. Switching Regimens in the Setting of Virologic Suppression
Didactic Series Switching Regimens in the Setting of Virologic Suppression Craig Ballard, PharmD, AAHIVP UC San Diego Health Owen Clinic June 14 th, 2018 1 Learning Objectives 1) Describe DHHS guidelines
More informationSingle Pill Combinations Versus Generics: Prescribing Practices in a New Healthcare Era
Activity Code FM285 Single Pill Combinations Versus Generics: Prescribing Practices in a New Healthcare Era Monica Gandhi MD, MPH Clinic Director, Ward 86 HIV Clinic, SFGH/UCSF Learning Objectives Upon
More informationClinical Management of Resistance. AMJ Wensing, MD, PhD
Clinical Management of Resistance AMJ Wensing, MD, PhD Changing treatment paradigm First Line Second Line? New First Line North America Western Europe: Eastern Europe Africa mix South America mix More
More informationUpdate on HIV Drug Resistance. Daniel R. Kuritzkes, MD Division of Infectious Diseases Brigham and Women s Hospital Harvard Medical School
Update on HIV Drug Resistance Daniel R. Kuritzkes, MD Division of Infectious Diseases Brigham and Women s Hospital Harvard Medical School Learning Objectives Upon completion of this presentation, learners
More informationAntiretroviral Dosing in Renal Impairment
Protease Inhibitors (PIs) Atazanavir Reyataz hard capsules 300 mg once daily taken with ritonavir 100 mg once daily No dosage adjustment is needed for atazanavir in renal impairment Atazanavir use in haemodialysis
More informationHIV Pharmacology 101ish - 202ish: New HIV Clinicians Workshop
HIV Pharmacology 101ish - 202ish: New HIV Clinicians Workshop Parya Saberi, PharmD, MAS The Medical Management of HIV/AIDS December 2012 Objectives What are commonly used ARVs and where do they work in
More informationHepatitis B Case Studies
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Hepatitis B Case Studies Nina Kim, MD MSc Associate Professor of Medicine University of Washington Harborview Madison Clinic and Hepatitis & Liver Clinic No
More informationCrafting an ART Regimen for Initiation or Salvage: Are NRTI s Necessary?
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Crafting an ART Regimen for Initiation or Salvage: Are NRTI s Necessary? Brian R. Wood, MD Assistant Professor of Medicine, University of Washington Medical
More informationSelecting an Initial Antiretroviral Therapy (ART) Regimen
Selecting an Initial Antiretroviral Therapy (ART) Regimen An HIV Diagnosis is a Call to Action In support of the NYSDOH AIDS Institute s January 2018 call to action for patients newly diagnosed with HIV,
More informationKimberly Adkison, 1 Lesley Kahl, 1 Elizabeth Blair, 1 Kostas Angelis, 2 Herta Crauwels, 3 Maria Nascimento, 1 Michael Aboud 1
Pharmacokinetics of Dolutegravir and Rilpivirine After Switching to the Two-Drug Regimen From an Efavirenz- or Nevirapine- Based Antiretroviral Regimen: SWORD-1 & -2 Pooled PK Analysis Kimberly Adkison,
More informationINDUCTION/MAINTENANCE Clinical Case
INDUCTION/MAINTENANCE Clinical Case Dr. Jose R Arribas @jrarribas INDUCTION/MAINTENANCE (more or less) Dr. Jose R Arribas @jrarribas Disclosures Speaker s Bureau: Viiv, Janssen, Abbvie, BMS, Gilead, MSD
More informationSELECTING THE BEST ART FOR EACH PATIENT
SELECTING THE BEST ART FOR EACH PATIENT Corklin R Steinhart, MD, PhD Head, Global Medical Directors ViiV Healthcare CNVX/HIVP/0025/16 5th Asian Conference on Hepatitis & AIDS 第五届亚洲肝炎与艾滋病学术会议 28-29 May
More informationAntiretroviral Drugs
Antiretroviral Drugs Dr Paddy Mallon UCD HIV Molecular Research Group Associate Dean for Research and Innovation UCD School of Medicine and Medical Science paddy.mallon@ucd.ie UCD School of Medicine &
More informationDidactic Series. Archive Genotype Resistance Testing in the Setting of Regimen Switching
Didactic Series Archive Genotype Resistance Testing in the Setting of Regimen Switching Craig Ballard, Pharm.D., AAHIVP UCSD Medical Center Owen Clinic June 11, 2015 ACCREDITATION STATEMENT: University
More informationThe ART of Managing Drug-Drug Interactions in Patients with HIV
The ART of Managing Drug-Drug Interactions in Patients with HIV Bradley L. Smith, Pharm.D. smith.bradley1@mayo.edu Pharmacy Grand Rounds December 19, 2017 2017 MFMER slide-1 Presentation Objectives Describe
More informationManagement of NRTI Resistance
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Management of NRTI Resistance David Spach, MD Principal Investigator, NW AETC Professor of Medicine, Division of Infectious Diseases University of Washington
More informationThe BATAR Study Boosted Atazanavir Truvada vs. Atazanavir Raltegravir
The BATAR Study Boosted Atazanavir Truvada vs. Atazanavir Raltegravir A Pilot Study of the Novel Antiretroviral Combination of Atazanavir and Raltegravir in HIV-1 Infected Subjects with Virologic Suppression
More informationDr Carole Wallis, PhD Medical Director, BARC-SA Head of the Specialty Molecular Division, Lancet Laboratories, South Africa
Dr Carole Wallis, PhD Medical Director, BARC-SA Head of the Specialty Molecular Division, Lancet Laboratories, South Africa Transmitted drug resistance Resistance patterns in first-line failures in adults
More informationDisclosures. Introduction to ARV Drug Resistance New Clinicians Workshop. Introduction. ARS Question 12/6/2017
Disclosures Introduction to ARV Drug Resistance New Clinicians Workshop I have no disclosures Susa Coffey, MD Division of HIV, ID and Global Medicine ARS Question Which resistance test do you order for
More informationCriteria for Oral PrEP
Oral PrEP New Drugs Roy M. Gulick, MD, MPH Chief, Division of Infectious Diseases Professor of Medicine Weill Medical College of Cornell University New York City Safe Criteria for Oral PrEP Penetrates
More informationVirological suppression and PIs. Diego Ripamonti Malattie Infettive - Bergamo
Virological suppression and PIs Diego Ripamonti Malattie Infettive - Bergamo Ritonavir-boosted PIs Boosted PIs: 3 drugs in one The intrinsic antiretroviral activity Viral suppression and high baseline
More informationDisclosures. Introduction to ARV Drug Resistance New Clinicians Workshop 12/9/16. Introduction. ARS Question
Disclosures Introduction to ARV Drug Resistance New Clinicians Workshop I have no disclosures Susa Coffey, MD Division of HIV, ID and Global Medicine ARS Question Which resistance test do you order for
More informationDolutegravir-Rilpivirine (Juluca)
Dolutegravir-Rilpivirine (Juluca) David H. Spach, MD Clinical Director, MW AETC Professor of Medicine Division of Infectious Diseases University of Washington Last Updated: November 30, 2017 ANTIRETROVIRAL
More informationThe Use of Integrase Inhibitors In Latin America: From Guidelines to the Real World Ernesto Martínez B., MD Internal Medicine, Infectious Diseases
De afbeelding kan niet worden weergegeven. The Use of Integrase Inhibitors In Latin America: From Guidelines to the Real World Ernesto Martínez B., MD Internal Medicine, Infectious Diseases DISCLOSURE
More informationUpdate on CADO/PADO: what are the challenges in using the current guidelines and foreseen ARV revisions: opportunities and challenges
Update on CADO/PADO: what are the challenges in using the current guidelines and foreseen ARV revisions: opportunities and challenges Treatment and Care Team Meg Doherty, Marco Vitoria, Martina Penazzato,
More informationARV Consolidated Guidelines 2015
ARV Consolidated Guidelines 2015 This document outlines the draft list of PICO questions to support systematic review process for the 2015 ARV guidelines process. PICO questions are grouped by clinical
More informationWhat next? Francois Venter. ART new drugs, new studies. Wits Reproductive Health & HIV Institute
Thanks: Polly Clayden, Francesca Conradie, Loyd Mulenga, Gary Maartens, Andrew Hill, David Ripin, Elli Katabira, Chris Duncombe, Nathan Ford, Marco Vitoria, WHO Industry: Gilead, Janssen, ViivV Abbott,
More informationDisclosures. Goals. US DHHS Guidelines: 1 st Line Therapy. Antiretroviral Therapy Initiation:
Disclosures Antiretroviral Therapy Initiation: From Guidelines to Practice: ART 101 Medical Management of AIDS & Hepatitis December 8, 2017 Research grant support from Gilead Sciences for ongoing work
More information/AIDS HIV/ HIV Overview. Nelson L. Michael, MD, PhD Division of Retrovirology Walter Reed Army Institute of Research US Military HIV Research Program
/AIDS HIV/ HIV Overview Nelson L. Michael, MD, PhD Division of Retrovirology Walter Reed Army Institute of Research US Military HIV Research Program www.hivresearch.org 1 WRAIR Tropical Medicine Course
More informationPAEDIATRIC HIV INFECTION. Dr Ashendri Pillay Paediatric Infectious Diseases Specialist
PAEDIATRIC HIV INFECTION Dr Ashendri Pillay Paediatric Infectious Diseases Specialist Paediatric HIV Infection Epidemiology Immuno-pathogenesis Antiretroviral therapy Transmission Diagnostics Clinical
More informationSINGLE. Efficacy and safety of dolutegravir (DTG) in treatment-naïve subjects
SINGLE Efficacy and safety of dolutegravir (DTG) in treatment-naïve subjects SE/HIV/0023/14 January 2014 PHASE III DTG TRIALS IN TREATMENT-NAÏVE ADULT SUBJECTS WITH HIV SINGLE 1 N=833 Phase III non-inferiority,
More informationDr Andrew Ustianowski
BHIVA AUTUMN CONFERENCE 2014 Including CHIVA Parallel Sessions Dr Andrew Ustianowski North Manchester General Hospital 9-10 October 2014, Queen Elizabeth II Conference Centre, London BHIVA AUTUMN CONFERENCE
More informationClinical skills building - HIV drug resistance
Clinical skills building - HIV drug resistance Richard Lessells Clinical case 44-year old HIV-positive male HIV diagnosis 2010 Pre-treatment CD4+ count not known Initiated first-line ART (TDF/FTC/EFV)
More informationOutline. A 41 Year-old Male COMMON PITFALLS IN HIV/AIDS MANAGEMENT: A CASE-BASED APPROACH. Q1: What anti-fungal regimen would you start?
Outline COMMON PITFALLS IN HIV/AIDS MANAGEMENT: A CASE-BASED APPROACH Considerations for antiretroviral use in patients with coinfections Concerning and how to manage drug-drug interactions ARV-other drugs
More informationPersistent low level viraemia on third line ART
Persistent low level viraemia on third line ART Dr Richard Lessells XXVII International workshop on HIV drug resistance and treatment strategies October 2018 46-year old HIV-positive female HIV diagnosis
More informationAntiretroviral Therapy: Panel Discussion
disclosures Antiretroviral Therapy: Panel Discussion Medical Management of HIV December 9, 217 Panelists: Harry Lampiris, MD; Annie Luetkemeyer, MD; Carina Marquez, MD Moderator: Oliver Bacon, MD none
More informationClinical support for reduced drug regimens. David A Cooper The University of New South Wales Sydney, Australia
Clinical support for reduced drug regimens David A Cooper The University of New South Wales Sydney, Australia Clinical support for reduced drug regimens First line optimisation Virological failure New
More informationCNS Toxicity of Integrase Inhibitors Myth or Reality? Ignacio Pérez Valero Unidad de VIH. Hospital U. La Paz
CNS Toxicity of Integrase Inhibitors Myth or Reality? Ignacio Pérez Valero Unidad de VIH. Hospital U. La Paz Question for the audience Do you think that any integrase inhibitor drug produce CNS adverse
More informationCase 1 continued. Case 1 (cont) 12/8/16. MMAH Debate Panel Thursday, December 8, Case 1
MMAH Debate Panel Thursday, December 8, 2016 Case 1 HPI 55 yo man with newly diagnosed HIV initiates care in your clinic. His CD4+ cell count is 600, with HIV VL=90,000 copies/ml. He is asymptomatic at
More informationUnmet needs and challenges of current ART in South Africa. Michelle Moorhouse 21 Nov 2015
Unmet needs and challenges of current ART in South Africa Michelle Moorhouse 21 Nov 2015 SA Snapshot Òct 2015 6-7 million HIV-positive: 18% world total, 25% of Southern Africa 3.2 on first line ART: consume
More informationStatistical issues in HIV trial design. Andrew Hill Senior Visiting Research Fellow Liverpool University
Statistical issues in HIV trial design Andrew Hill Senior Visiting Research Fellow Liverpool University Type 1 error It is statistically significant! (after 100 different statistical tests) Type 1 error:
More informationSupplementary Data. Supplementary Table S2. Antiretroviral Therapies Taken with Ledipasvir/Sofosbuvir
Supplementary Data Statistical Analysis Due to the limited number of patients with acute kidney injury and concern for model overfitting, covariates included in multivariable logistic regression analyses
More informationProfessor Jeffery Lennox
BHIVA AUTUMN CONFERENCE 2014 Including CHIVA Parallel Sessions Professor Jeffery Lennox Emory University School of Medicine Atlanta, Georgia, USA 9-10 October 2014, Queen Elizabeth II Conference Centre,
More information